C Fernandez-Miranda

Summary

Country: Spain

Publications

  1. ncbi A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
    C Fernández-Miranda
    Services of Internal Medicine Lipid and Atherosclerosis Unit, Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Avda de Córdoba s n, 28041 Madrid, Spain
    Dig Liver Dis 40:200-5. 2008
  2. ncbi Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease
    Consuelo Fernández-Miranda
    Hospital Universitario 12 de Octubre, Madrid, Service of Internal Medicine Lipid and Atherosclerosis Unit, Madrid, Spain
    Int J Cardiol 118:345-9. 2007
  3. ncbi Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid
    C Fernandez-Miranda
    Services of Internal Medicine, Lipids Unit, Renal Transplant Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
    Clin Transplant 14:110-4. 2000
  4. ncbi Lipoprotein abnormalities in patients with asymptomatic acute porphyria
    C Fernandez-Miranda
    Servicio de Medicina Interna, Unidad de Lipidos, Hospital Universitario 12 de Octubre, 28041, Madrid, Spain
    Clin Chim Acta 294:37-43. 2000
  5. ncbi [Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia]
    C Fernandez-Miranda
    Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid
    Rev Clin Esp 205:489-92. 2005
  6. ncbi [New perspectives in the measurement of cardiovascular risk: explorations to detect subclinical atherosclerosis and inflammation markers]
    Consuelo Fernández-Miranda
    Unidad de Lípidos y Aterosclerosis, Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain
    Med Clin (Barc) 128:344-51. 2007
  7. ncbi Hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C-->T and 1298A-->C mutations in patients with inflammatory bowel disease
    C Fernandez-Miranda
    Department of Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain
    Rev Esp Enferm Dig 97:497-504. 2005
  8. ncbi [Hyperhomocysteinemia and treatment with antiepileptic drugs. Effects of different doses of folic acid]
    Consuelo Fernández-Miranda
    Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain
    Med Clin (Barc) 124:521-4. 2005
  9. ncbi [Effect of hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C --> T mutation in venous thromboembolism risk of young adults]
    Consuelo Fernández-Miranda
    Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain
    Med Clin (Barc) 124:532-4. 2005
  10. ncbi Apolipoprotein E polymorphism and carotid atherosclerosis in patients with coronary disease
    Consuelo Fernández-Miranda
    Services of Internal Medicine Lipid and Atherosclerosis Unit, Hospital Universitario 12 de Octubre, Ctra Andalucía km 5 4, 28041 Madrid, Spain
    Int J Cardiol 94:209-12. 2004

Collaborators

  • Agustín Gómez De La Cámara
  • J A Solis-Herruzo
  • C Fernández-Miranda
  • Consuelo Fernández-Miranda
  • G López-Alonso
  • F Colina
  • J A Solís-Herruzo
  • C Vargas
  • M Pérez-Carreras
  • Victor Núñez
  • José Luis Aranda
  • Agustín Gómez de la Cámara
  • Joaquin Arenas
  • Miguel Angel Martín

Detail Information

Publications10

  1. ncbi A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
    C Fernández-Miranda
    Services of Internal Medicine Lipid and Atherosclerosis Unit, Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Avda de Córdoba s n, 28041 Madrid, Spain
    Dig Liver Dis 40:200-5. 2008
    ..Dyslipidaemia and insulin resistance are two important risk factors for non-alcoholic fatty liver disease. Both factors can improve with fenofibrate...
  2. ncbi Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease
    Consuelo Fernández-Miranda
    Hospital Universitario 12 de Octubre, Madrid, Service of Internal Medicine Lipid and Atherosclerosis Unit, Madrid, Spain
    Int J Cardiol 118:345-9. 2007
    ..The aim of this study was to evaluate the effect of folic acid treatment on the evolution of CIMT in patients with coronary disease and homocysteinemia > or =9 micromol/l...
  3. ncbi Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid
    C Fernandez-Miranda
    Services of Internal Medicine, Lipids Unit, Renal Transplant Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
    Clin Transplant 14:110-4. 2000
    ..Folic acid therapy produces a significant decrease in homocysteine concentrations, in the absence of clear folate deficiency, without differences in relation to immunosuppressant therapy...
  4. ncbi Lipoprotein abnormalities in patients with asymptomatic acute porphyria
    C Fernandez-Miranda
    Servicio de Medicina Interna, Unidad de Lipidos, Hospital Universitario 12 de Octubre, 28041, Madrid, Spain
    Clin Chim Acta 294:37-43. 2000
    ..05). In conclusion, in patients with asymptomatic acute porphyria an increase of total and LDL-cholesterol was found. The cardiovascular risk conferred by this factor may be attenuated by increased HDL-cholesterol and apo-A1...
  5. ncbi [Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia]
    C Fernandez-Miranda
    Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid
    Rev Clin Esp 205:489-92. 2005
    ..Vitamin B12 is among its main causes and may be due to a pernicious anemia. This study aimed to know the prevalence of this disease in patients who have venous thromboembolism and hyperhomocysteinemia...
  6. ncbi [New perspectives in the measurement of cardiovascular risk: explorations to detect subclinical atherosclerosis and inflammation markers]
    Consuelo Fernández-Miranda
    Unidad de Lípidos y Aterosclerosis, Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain
    Med Clin (Barc) 128:344-51. 2007
    ..In this article, the current state of knowledge about these explorations and the guidelines of the main scientific societies are reviewed, and the practical conclusions of the working group are provided...
  7. ncbi Hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C-->T and 1298A-->C mutations in patients with inflammatory bowel disease
    C Fernandez-Miranda
    Department of Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain
    Rev Esp Enferm Dig 97:497-504. 2005
    ..The aim of this study was the assessment of hyperhomocysteinemia in patients with IBD and its relation among vitamin B12 and folate levels, and methylenetetrahydrofolate reductase (MTHFR) 677C-->T and 1298A-->C mutations...
  8. ncbi [Hyperhomocysteinemia and treatment with antiepileptic drugs. Effects of different doses of folic acid]
    Consuelo Fernández-Miranda
    Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain
    Med Clin (Barc) 124:521-4. 2005
    ..The aims of this study were: 1) to assess the frequency and determinant factors of hyperhomocysteinemia in adult patients receiving antiepileptic drugs, and 2) to know the effect of different doses of folic acid...
  9. ncbi [Effect of hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C --> T mutation in venous thromboembolism risk of young adults]
    Consuelo Fernández-Miranda
    Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Spain
    Med Clin (Barc) 124:532-4. 2005
    ..To investigate whether hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) 677C --> T mutation are associated with venous thromboembolism in young Spanish adults...
  10. ncbi Apolipoprotein E polymorphism and carotid atherosclerosis in patients with coronary disease
    Consuelo Fernández-Miranda
    Services of Internal Medicine Lipid and Atherosclerosis Unit, Hospital Universitario 12 de Octubre, Ctra Andalucía km 5 4, 28041 Madrid, Spain
    Int J Cardiol 94:209-12. 2004
    ..The aim of this study was to evaluate the role of apo E polymorphism in the development of subclinical carotid atherosclerosis in patients with coronary disease...